


# TOWARDS AN IN VITRO MODEL OF EARLY ALZHEIMER'S DISEASE PATHOLOGY


Agalic Rodriguez-Duboc<sup>1,2,3</sup>, Katja Scheffler<sup>1,4,5</sup>, Ida Johansson<sup>5</sup>, Axel Nyman<sup>2,5</sup>,  
Gøril Rolfseng Grøntvedt<sup>1,2,3,5</sup>, and Asgeir Kibro-Flatmoen<sup>1,2,3</sup>

<sup>1</sup> Nasjonalforeningens Demensforskningscenter, NTNU, Norway  
<sup>2</sup> K. G. Jebsen Centre for Alzheimer's Disease, NTNU, Norway  
<sup>3</sup> Kavli Institute for Systems Neuroscience, NTNU, Norway  
<sup>4</sup> Department of Neuromedicine and Movement Science, NTNU, Norway  
<sup>5</sup> Department of Neurology, Trondheim University Hospital, Norway




## INTRODUCTION: Focusing on the Lateral Entorhinal Cortex

Cortical onset of AD → reelin expressing (Re+) projection neurons in layer II (LII) of the lateral entorhinal cortex (LEC)<sup>1,2</sup>.



## METHODS: In vitro model of early AD



## OBJECTIVES: develop a versatile neuronal culture platform




## RESULTS: Inducing differentiation

Marker	Relevant Function
RELN	Neuronal development <sup>7</sup>
CTIP2	Neuronal development <sup>7</sup>
PENK	Neuronal development <sup>7</sup>
GRIK1	Glutamate receptor, ionotropic, kainate 1 <sup>12</sup>



Co-expression → thought to form a specific Re+LECLII molecular signature

20-day old cells derived from healthy volunteers + extrinsic factors → express CTIP2 and GRIK1 (known to be expressed in LECLII neurons).

This suggests that with the extrinsic factors alone, the cells begin their differentiation but do not reach the desired phenotype.




24-day old cells derived from healthy volunteers + extrinsic + intrinsic factors → cells clearly express reelin, CTIP2, GluR5, but PENK is less conclusive.




Suggesting the need for a longer time in culture or an adjustment in the factors.

## FUTURE PERSPECTIVES AND NEXT STEPS


1 Survival times pose a challenge and must be further improved to allow characterization.  
→ Co-culture with astrocytes.



2 Test interactions with healthy versus AD astrocytes.



3 Apply bulk transcriptomics and test associated pathways with/without intervention on selected targets.



## REFERENCES

1. Kibro-Flatmoen, *Ageing Res Rev.* 2021  
2. Kibro-Flatmoen, *J Alzheimers Dis.* 2023  
3. Montiel, *Front Neurosci.* 2015  
4. Sakaguchi, *Nat Commun.* 2015  
5. Assimacopoulos, *J Neurosci.* 2003  
6. Bishop, *Science.* 2000  
7. Bergmann, *Front Cell Dev Biol.* 2022  
8. Sugo, *Eur J Neurosci.* 2010  
9. Allen Brain Atlas: *Experiment 71920429*  
10. Du, *Nat Commun.* 2019  
11. Crespo, *Mol Neurobiol.* 2022  
12. Yao, *Cell.* 2021